Drugmakers scramble to boost leukemia drug supply; Ex-GSK lawyer indicted again;

@FiercePharma: HHS moves to bar Forest CEO from pharma. Story | Follow @FiercePharma

> Hospira, Fresenius and Boehringer Ingelheim are racing to restore U.S. supplies of a scarce leukemia drug while regulators look to imports to meet patient demand. News

> Lauren Stevens, a former lawyer for GlaxoSmithKline, has been reindicted for obstructing a probe into the company's marketing practices after the first indictment was dismissed because of errors by prosecutors. Report

> Indian business officials expect the subcontinent's pharmaceutical industry to reach $20 billion by 2015, making it one of the world's top 10 drug markets. Report

> Cubist Pharmaceuticals posted better-than-expected quarterly earnings driven by strong U.S. and international sales of its flagship antibiotic injection Cubicin, sending its shares up four percent. Story

> Genzyme, a subsidiary of Sanofi-Aventis, has sued two companies for patent infringement related to its Synvisc osteoarthritis product. News

> North Carolina Attorney General Roy Cooper warned that a measure giving immunity to pharmaceutical companies could cost state taxpayers what one legislator described as "hundreds of millions of dollars." Release

> European drug regulators recommended lifting a suspension on Octapharma's immunoglobulin treatment Octagam, allowing the medicine back onto the market in the EU. Item

> For the second time in five years, Public Citizen is petitioning the FDA to ban Roche's Xenical prescription diet pill, which is also marketed by GlaxoSmithKline in a lower-dose, over-the-counter version known as Alli. Report

Biotech News

 @FierceBiotech: Does Eisai's epilepsy drug work? Yes and no. Item | Follow @FierceBiotech

> Lilly, Amylin win EU recommendation for Bydureon. News

> Ex-CEO of InterMune sentenced in fraud case. Story 

> Pfizer's potential blockbuster RA drug reports Phase III success. Item

>  Galapagos ditches its experimental arthritis drug. Report

> After 20 years, Human Genome Sciences nears profitability. Story 

> Biotech VC dollars rise, but deal numbers fall. Item 

And Finally... Astronaut warning: Some drugs intended to treat minor illnesses in space may have shorter shelf lives there than they do on Earth. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.